Quzhou Population Cohort Research Project (Aging Related Research: Intervention of Nicotinamide Mononucleotide in Middle-aged and Elderly People)
NCT ID: NCT06592859
Last Updated: 2025-06-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
240 participants
INTERVENTIONAL
2023-08-23
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Impact of Nicotinamide Mononucleotide Sustained-release Tablets on Immunosenescence and Metablism in Middle-aged and Elderly Individuals With Metabolic Disorders.
NCT06907329
To Evaluate the Efficacy and Safety of NMN as an Anti-ageing Supplement in Middle Aged and Older (40-65 Years) Adults
NCT04823260
Effectiveness of Qualia NAD+ Supplementation on Intracellular NAD Levels
NCT06505967
Safety & Efficacy of Nicotinamide Riboside Supplementation for Improving Physiological Function in Middle-Aged and Older Adults
NCT02921659
Effect of "Nicotinamide Mononucleotide" (NMN) on Cardiometabolic Function
NCT03151239
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
NMN Arm
NMN Arm participants took one capsule (containing 350mg NMN) with breakfast daily for one year.
NMN
NMN Arm participants took one capsule (containing 350mg NMN or placebo) with breakfast daily for one year.
Placebo Arm
Placebo arm participants took one capsule (appearance and odor are the same as NMN) with breakfast daily for one year.
placebo
Placebo arm participants took one capsule (appearance and odor are the same as NMN) with breakfast daily for one year.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
NMN
NMN Arm participants took one capsule (containing 350mg NMN or placebo) with breakfast daily for one year.
placebo
Placebo arm participants took one capsule (appearance and odor are the same as NMN) with breakfast daily for one year.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. age 40-50 and 60-70 years old, no major bad habits.
3. Gender unlimited.
4. in good health and has not undergone major surgery within half a year.
5. Be able to communicate well with researchers and cooperate with the work during the study.
6. Written informed consent can be signed voluntarily.
Exclusion Criteria
2. Participants are conducting other clinical trials or using any research drugs or equipment for treatment within 30 days before enrollment (including but not limited to aspirin, metformin, resveratrol, vitamin C, etc.).
3. Obesity (bmi more than 30).
4. Pregnant/lactating women.
5. Disease history:
A) under 60 years old:
1. any cancer (erythrocytosis, except basal cell or squamous cell skin cancer).
2. coronary artery disease/myocardial infarction/clinically significant congestive heart failure.
3. stroke/transient ischemic attack.
4. deep vein thrombosis/pulmonary embolism.
5. serum creatinine \> 1.5 mg/dl (male).
6. poor control of hypertension (although treated, there is still significant hypertension (systolic blood pressure \> 160 mmHg, or diastolic blood pressure \>100 mmHg)).
7. history of active liver disease or metabolic acidosis.
8. chronic kidney disease/hemodialysis treatment, history of severe kidney damage and/or EGFR ≤ 45ml/min/1.73m2.
9. severe autoimmunity/inflammation, such as rheumatoid arthritis, lupus, Crohn\'s disease, etc.
10. nervous system diseases such as dementia, such as Alzheimer/Parkinson\'s disease.
11. diabetes mellitus (hemoglobin \> 6.5% or fasting blood glucose \> 126 mg/dL or taking diabetes drugs or insulin treatment).
12. recent (within 3 months) cardiovascular events (myocardial infarction, coronary intervention, coronary artery bypass grafting).
13. infectious diseases such as HIV, hepatitis, tuberculosis, etc.
14. hand or lower limb disability affects normal function and life.
B) older than 60 years:
1. any cancer (erythrocytosis, except basal cell or squamous cell skin cancer).
2. history of active liver disease or metabolic acidosis.
3. chronic kidney disease/hemodialysis treatment, history of severe kidney damage and/or EGFR ≤ 45ml/min/1.73m2.
4. severe autoimmunity/inflammation, such as lupus, Crohn\'s disease, etc.
5. nervous system diseases such as dementia, such as Alzheimer/Parkinson\'s disease.
6. recent (within 3 months) cardiovascular events (myocardial infarction, coronary intervention, coronary artery bypass grafting).
7. infectious diseases such as HIV, hepatitis, tuberculosis, etc.
8. hand or lower limb disability affects normal function and life.
6. Currently taking the following drugs regularly:
A) chemotherapy drugs (such as tamoxifen, adriamycin, mitoxantrone, bleomycin). B) antiplatelet drugs (e.g., clopidogrel/Plavix, dipyridamole/anglionide, ticlopidine/ticlopidine, except aspirin).
C) cholinesterase inhibitors for Alzheimer\'s disease (donepezil/alicept).
7. The researchers believe that the physical factors of the participants may have an adverse impact on the research process or results.
40 Years
70 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Beijing Institute of Genomics, Chinese Academy of Sciences
OTHER_GOV
Institute of Zoology, Chinese Academy of Sciences
OTHER_GOV
People's Hospital of Quzhou
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Feng Zhang
researcher
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
People's Hospital of Quzhou
Quzhou, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MR-33-24-001563
Identifier Type: OTHER
Identifier Source: secondary_id
2023-049
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.